N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide | 1119800-42-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide
• 英文别名: N-[4-[4-(6-butylquinolin-8-yl)oxypiperidin-1-yl]butyl]ethanesulfonamide
• CAS: 1119800-42-8
• 化学式: C₂₄H₃₇N₃O₃S
• 分子量: 447.642
• InChiKey: YIJMYSUOYUNZGL-UHFFFAOYSA-N

物化性质

• 沸点：
  604.7±65.0 °C(predicted)
• 密度：
  1.137±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  31
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  79.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide 在 盐酸 作用下， 以 甲醇 为溶剂， 以63%的产率得到N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide dihydrochloride
  参考文献：
  名称：

  Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis

  摘要：

  A series of potent, selective and long-acting quinoline-based sulfonamide human H-1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H-1 receptor than azelastine, had low oral bioavailability in the rat and dog, and was turned over to five major metabolites. Furthermore, 33b had longer duration of action than azelastine in guinea pigs, lower rat brain-penetration, and did not cause time dependent inhibition of CYP2D6 or CYP3A4. The clinical dose in humans is expected to be low (approximately 0.5 mg per day) based on the clinical dose used for azelastine and a comparison of efficacy data from animal models for 33b and azelastine. (C) 2017 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2017.09.020
• 作为产物：
  描述：

  6-butyl-8-(piperidin-4-yloxy)quinoline 在 盐酸 、 potassium carbonate 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 丁酮 为溶剂， 反应 25.0h， 生成 N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide
  参考文献：
  名称：

  Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis

  摘要：

  A series of potent, selective and long-acting quinoline-based sulfonamide human H-1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H-1 receptor than azelastine, had low oral bioavailability in the rat and dog, and was turned over to five major metabolites. Furthermore, 33b had longer duration of action than azelastine in guinea pigs, lower rat brain-penetration, and did not cause time dependent inhibition of CYP2D6 or CYP3A4. The clinical dose in humans is expected to be low (approximately 0.5 mg per day) based on the clinical dose used for azelastine and a comparison of efficacy data from animal models for 33b and azelastine. (C) 2017 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2017.09.020

文献信息

• Compounds
  申请人：Gore Paul Martin

  公开号：US20090270355A1

  公开（公告）日：2009-10-29

  The present invention relates to a compound which is N-(4-4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide and salts thereof, processes for its preparation, to compositions containing it and to its use in the treatment of various diseases, such as allergic rhinitis.

  本发明涉及一种化合物，即N-(4-4-[(6-丁基-8-喹啉基)氧基]-1-哌啶基}丁基)乙烷磺酰胺及其盐，以及其制备方法、含有该化合物的组合物，以及在治疗各种疾病（如过敏性鼻炎）中的用途。
• SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS
  申请人：Gore Paul Martin

  公开号：US20110281909A1

  公开（公告）日：2011-11-17

  The present invention relates to compounds of formula (I), and salts thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various diseases, such as allergic rhinitis.

  本发明涉及公式（I）的化合物及其盐，其制备方法，含有它们的组合物以及它们在治疗各种疾病（如过敏性鼻炎）中的应用。
• N-Cyclobutyl - Imidazopyridine - Methylamine As TRPV1 Antagonists
  申请人：Biggadike Keith

  公开号：US20140051720A1

  公开（公告）日：2014-02-20

  A compound of formula (I) wherein X represents a H atom, or a CH 2 OH group, Y represents a H atom, or a CH 2 OH group, but X and Y are not both CH 2 OH groups and Ar is selected from or a pharmaceutically acceptable salt thereof.

  化合物的化学式为(I)，其中X代表氢原子或CH2OH基团，Y代表氢原子或CH2OH基团，但X和Y不同时为CH2OH基团，Ar从下列中选择，或其药学上可接受的盐。
• The TRPVL Antagonists SB-795498 For Treating Rhinitis
  申请人：Bountra Charanjit

  公开号：US20110200646A1

  公开（公告）日：2011-08-18

  The present invention relates to the use of urea compound in the treatment of rhinitis, to aqueous pharmaceutical compositions containing said compound, in particular to compositions suitable for intranasal administration.
• US7884114B2
  申请人：——

  公开号：US7884114B2

  公开（公告）日：2011-02-08